Failure of plasma therapy in Covid-19

Dear Editor, we would like to share ideas on the publication “Has plasma therapy failed in Covid-19 or we have failed in using it properly in India? -lessons learned through the pandemic [1].” Datta and Chakrabarty proposed that “the collection of high titer CP by using a centralized inventory system and its administration to Covid-19 patients early in their illnesses could significantly benefit India as a nation to manage the ongoing pandemic situation and it may also reduce the bed crisis in the hospitals by decreasing the length of ICU sta [1].” CP use might or might not useful for management of COVID-19 but the safety is still an important consideration [2]. Antibody in plasma plays important role in plasma therapy therefore, collection of plasma with high antibody titer is important. However, the antibody response in different individual is different and the donation must be volunteer, hence, it is very difficult to have a specific plasma collection at a specific date after illness. In addition, the main problem at present is variants of COVID-19. Plasma from a COVID-19 recovery case of a classical infection or a variant might be useless for infection by other SARS CoV-2 variants [3].

Disclosure of interest

The authors declare that they have no competing interest.